Lupin gets UK MHRA Approval of ‘Lutio' for Treatment of COPD; stock slips ~1.5%

26 Aug 2022 , 01:03 PM

Lupin Limited (Lupin) today announced that its UK subsidiary, Lupin Healthcare (UK) Limited, has obtained Medicines and Healthcare products Regulatory Agency (MHRA) authorization to commercialize a generic version of Spiriva.

When made available to UK patients, Lutio has the potential to provide considerable cost reductions.

Tiotropium is used to treat wheezing, shortness of breath, coughing, and chest tightness in people who have a chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema.

“We are delighted that the MHRA has approved Lutio for the treatment of chronic obstructive pulmonary disease (COPD), giving patients in the UK with an effective and high-quality therapeutic choice,” said Thierry Volle, Lupin’s President, EMEA.

This is Lupin Healthcare’s second inhalation product for the UK market after the Luforbec pressurized metered dosage inhaler (pMDI).

At around 1.06 PM, Lupin was trading at Rs656 down by Rs9 or 1.35% from its previous closing of Rs665 on the BSE. The scrip touched intraday high and low of Rs672.95 and Rs655.65 respectively.

For feedback and suggestions, write to us at [e-mail]